Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 5:14:330.
doi: 10.3389/fnins.2020.00330. eCollection 2020.

Mechanisms of Dexmedetomidine in Neuropathic Pain

Affiliations
Review

Mechanisms of Dexmedetomidine in Neuropathic Pain

Yang Zhao et al. Front Neurosci. .

Abstract

Dexmedetomidin is a new-generation, highly selective α2 adrenergic receptor agonist with a large number of advantages, including its sedative and analgesic properties, its ability to inhibit sympathetic nerves, its reduced anesthetic dosage, its hemodynamic stability, its mild respiratory depression abilities, and its ability to improve postoperative recognition. Its safety and effectiveness, as well as its ability to provide a certain degree of comfort to patients, make it a useful anesthetic adjuvant for a wide range of clinical applications. For example, dexmedetomidine is commonly used in patients undergoing general anesthesia, and it also exerts sedative effects during tracheal intubation or mechanical ventilation in intensive care unit patients. In recent years, with the deepening of clinical research on dexmedetomidine, the drug is still applied in the treatment of spastic pain, myofascial pain, neuropathic pain, complex pain syndrome, and chronic headache, as well as for multimodal analgesia. However, we must note that the appropriateness of patient and dose selection should be given attention when using this drug; furthermore, patients should be observed for adverse reactions such as hypotension and bradycardia. Therefore, the safety and effectiveness of this drug for long-term use remain to be studied. In addition, basic experimental studies have also found that dexmedetomidine can protect important organs, such as the brain, heart, kidney, liver, and lung, through various mechanisms, such as antisympathetic effects, the inhibition of apoptosis and oxidative stress, and a reduction in the inflammatory response. Moreover, the neuroprotective properties of dexmedetomidine have received the most attention from scholars. Hence, in this review, we mainly focus on the characteristics and clinical applications of dexmedetomidine, especially the role of dexmedetomidine in the nervous system and the use of dexmedetomidine in the relief of neuropathic pain.

Keywords: adrenergic receptor; dexmedetomidine; neuropathic pain; neuroprotective effect; α2 adrenergic receptor.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Dexmedetomidine for neuropathic pain.

References

    1. Abd-Elshafy S. K., Abdallal F., Kamel E. Z., Edwar H., Allah E. A., Maghraby H. H. M., et al. (2019). Paravertebral dexmedetomidine in video-assisted thoracic surgeries for acute and chronic pain prevention. Pain Phys. 22 271–280. - PubMed
    1. Alam A., Suen K. C., Hana Z., Sanders R. D., Maze M., Ma D. (2017). Neuroprotection and neurotoxicity in the developing brain: an update on the effects of dexmedetomidine and xenon. Neurotoxicol. Teratol. 60 102–116. 10.1016/j.ntt.2017.01.001 - DOI - PubMed
    1. Andjelkovic L., Novak-Jankovic V., Pozar-Lukanovic N., Bosnic Z., Spindler-Vesel A. (2018). Influence of dexmedetomidine and lidocaine on perioperative opioid consumption in laparoscopic intestine resection: a randomized controlled clinical trial. J. Int. Med. Res. 46 5143–5154. 10.1177/0300060518792456 - DOI - PMC - PubMed
    1. Barends C. R., Absalom A., van Minnen B., Vissink A., Visser A. (2017). Dexmedetomidine versus midazolam in procedural sedation. a systematic review of efficacy and safety. PLoS One 12:e0169525. 10.1371/journal.pone.0169525 - DOI - PMC - PubMed
    1. Baron R. (2009). Neuropathic pain: a clinical perspective. Handb. Exp. Pharmacol. 194 3–30. 10.1007/978-3-540-79090-7_1 - DOI - PubMed

LinkOut - more resources